Metal–Organic Framework-Supported Catalase Delivery for Enhanced Photodynamic Therapy via Hypoxia Mitigation
Source abstract
Abstract
Tumor hypoxia poses a significant challenge in photodynamic therapy (PDT), which uses molecular oxygen to produce reactive oxygen species upon light excitation of a photosensitizer. For hypoxia mitigation, an enzyme catalase (CAT) can be beneficially used to convert intracellular hydrogen peroxide to molecular oxygen, but its utility is significantly limited due to the intrinsic membrane impermeability. Herein, we present direct integration of CAT into the outer surface of unmodified metal-organic framework (MOF) nanoparticles (NPs) via supramolecular interactions for effective cellular entry of CAT and consequent enhancement of PDT. The results demonstrated that CAT-loaded MOF NPs could successfully enter hypoxic cancer cells, after which the intracellularly delivered CAT molecules became dissociated from the MOF surface to efficiently initiate the oxygen generation and PDT process along with a co-delivered photosensitizer IR780. This achievement suggests that our protein-MOF integration strategy holds great potential in biomedical studies to overcome tumor hypoxia as well as to efficiently deliver biomolecular cargos.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Luminescence and Fluorescent Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea
Funding
Ulsan National Institute of Science and Technology · National Research Foundation of Korea
References (35)
Show source-provided references
1. 10.1038/nrc107110.1038/nrc1071 ↗
2. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
3. 10.2147/HP.S9341310.2147/HP.S93413 ↗
4. 10.1021/ja901857210.1021/ja9018572 ↗
5. 10.1016/S0141-0229(01)00505-110.1016/S0141-0229(01)00505-1 ↗
6. 10.1016/0032-9592(94)00066-210.1016/0032-9592(94)00066-2 ↗
7. 10.1007/s10555-020-09870-110.1007/s10555-020-09870-1 ↗
8. 10.1073/pnas.81.14.434310.1073/pnas.81.14.4343 ↗
9. 10.1073/pnas.110187410810.1073/pnas.1101874108 ↗
10. 10.1080/21645515.2015.110280410.1080/21645515.2015.1102804 ↗
11. 10.1016/j.jconrel.2006.05.01310.1016/j.jconrel.2006.05.013 ↗
12. 10.1039/C8CS00008E10.1039/C8CS00008E ↗
13. 10.1002/adma.20190279110.1002/adma.201902791 ↗
14. 10.1039/C7TB00244K10.1039/C7TB00244K ↗
15. 10.1021/nl072471q10.1021/nl072471q ↗
16. 10.1021/ja907887z10.1021/ja907887z ↗
17. 10.1016/j.jcis.2019.10.10010.1016/j.jcis.2019.10.100 ↗
18. 10.1002/adfm.20160631410.1002/adfm.201606314 ↗
19. 10.1021/acsami.1c0108910.1021/acsami.1c01089 ↗
20. 10.1002/advs.20180152610.1002/advs.201801526 ↗
21. 10.1021/acsbiomaterials.0c0160010.1021/acsbiomaterials.0c01600 ↗
22. 10.1039/D1CC05157A10.1039/D1CC05157A ↗
23. 10.1002/adfm.20160321210.1002/adfm.201603212 ↗
24. 10.1021/jacs.8b1030210.1021/jacs.8b10302 ↗
25. 10.1021/ja513058h10.1021/ja513058h ↗
26. 10.1021/acs.chemmater.2c0133810.1021/acs.chemmater.2c01338 ↗
27. 10.1021/jacs.6b1193410.1021/jacs.6b11934 ↗
28. 10.1021/jacs.0c0503910.1021/jacs.0c05039 ↗
29. 10.1038/s41467-018-06979-410.1038/s41467-018-06979-4 ↗
30. 10.1016/j.cej.2023.14435710.1016/j.cej.2023.144357 ↗
31. 10.1002/smll.20230021810.1002/smll.202300218 ↗
32. 10.1016/j.jcis.2023.06.17310.1016/j.jcis.2023.06.173 ↗
33. 10.1039/D2BM00010E10.1039/D2BM00010E ↗
34. 10.1021/ja408084j10.1021/ja408084j ↗
35. Szatrowski T. P. · Cancer Res. · 1991 · 51 · 794